Hormonal
For individuals with type 2 diabetes on single non-insulin medication, the maximum justifiable cost for a weight loss maintenance intervention is lower (£88.14) than for those with high BMI alone (£104.64) at an ICER of £20,000 per QALY.
For a person with type 2 diabetes on medication, a weight loss maintenance program is considered cost-effective if it costs less than approximately £88 per person. This is a lower threshold than for non-diabetics because the potential for long-term health gains (QALYs) is smaller for those who already have the disease.
The justifiable cost for a weight loss maintenance intervention at an ICER of £20,000 per QALY was £104.64 for an individual with a BMI of 28 or over and £88.14 for an individual with type 2 diabetes.
Why this rating
Based on the same economic model and meta-analysis data as N1.
Source
Using health economic modelling to inform the design and development of an intervention: estimating the justifiable cost of weight loss maintenance in the UK
Sarah Bates et al. · BMC Public Health · 2022
DOI 10.1186/s12889-022-12737-5
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →